Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Marseille, France.
Carenity, Paris, France.
J Clin Nurs. 2023 Sep;32(17-18):6460-6473. doi: 10.1111/jocn.16674. Epub 2023 Mar 7.
We aimed to identify correlates of cannabinoid-based products (CBP) use in patients with multiple sclerosis (MS) in France and Spain.
MS is responsible for a wide range of symptoms, including pain. Access to CBP differs according to local legislation. The French context is more restrictive than the Spanish one, and no data regarding cannabis use among MS patients has yet been published. Characterizing MS patients who use CBP constitutes a first step toward identifying persons most likely to benefit from them.
An online cross-sectional survey was submitted to MS patients who were members of a social network for people living with chronic diseases and were living in France or Spain.
Two study outcomes measured therapeutic CBP use and daily therapeutic CBP use. Seemingly unrelated bivariate probit regression models were used to test for associations between the outcomes and patients' characteristics while accounting for country-related differences. STROBE guidelines were followed in reporting this study.
Among 641 study participants (70% from France), the prevalence of CBP use was similar in both countries (23.3% in France vs. 20.1% in Spain). MS-related disability was associated with both outcomes, with a gradient observed between different degrees of disability. MS-related pain level was associated with CBP use only.
CBP use is common in MS patients from both countries. The more severe the MS, the more participants turned to CBP to alleviate their symptoms. Easier access to CBP should be ensured for MS patients in need of relief, especially from pain.
This study highlights the characteristics of MS patients using CBP. Such practices should be discussed by healthcare professional with MS patients.
我们旨在确定法国和西班牙多发性硬化症（MS）患者使用大麻素产品（CBP）的相关因素。
MS 会导致多种症状，包括疼痛。CBP 的获取因当地法规而异。法国的情况比西班牙更严格，而且尚未发表有关 MS 患者使用大麻的任何数据。描述使用 CBP 的 MS 患者是确定最有可能从中受益的人群的第一步。
一项在线横断面调查提交给了社交网络中患有慢性疾病并居住在法国或西班牙的 MS 患者。
两种研究结果衡量了治疗性 CBP 的使用和每日治疗性 CBP 的使用。似乎不相关的二元概率回归模型用于测试结果与患者特征之间的关联，同时考虑到与国家相关的差异。本研究遵循 STROBE 指南进行报告。
在 641 名研究参与者中（70%来自法国），两国的 CBP 使用率相似（法国为 23.3%，西班牙为 20.1%）。MS 相关残疾与两种结果均相关，在不同残疾程度之间观察到梯度。MS 相关疼痛水平仅与 CBP 使用相关。
两国的 MS 患者都普遍使用 CBP。MS 越严重，参与者就越倾向于使用 CBP 来缓解症状。应确保有缓解需求的 MS 患者更容易获得 CBP，特别是缓解疼痛。
本研究强调了使用 CBP 的 MS 患者的特征。医疗保健专业人员应与 MS 患者讨论此类做法。
